[go: up one dir, main page]

WO2011156610A3 - Quinoline and isoquinoline derivatives as inhibitors of hepatitis c virus - Google Patents

Quinoline and isoquinoline derivatives as inhibitors of hepatitis c virus Download PDF

Info

Publication number
WO2011156610A3
WO2011156610A3 PCT/US2011/039813 US2011039813W WO2011156610A3 WO 2011156610 A3 WO2011156610 A3 WO 2011156610A3 US 2011039813 W US2011039813 W US 2011039813W WO 2011156610 A3 WO2011156610 A3 WO 2011156610A3
Authority
WO
WIPO (PCT)
Prior art keywords
inhibitors
quinoline
hepatitis
virus
isoquinoline derivatives
Prior art date
Application number
PCT/US2011/039813
Other languages
French (fr)
Other versions
WO2011156610A2 (en
Inventor
Zhenhong R. Cai
Zhimin Du
Mingzhe Ji
Haolun Jin
Choung U. Kim
Michael R. Mish
Barton W. Phillips
Hyung-Jung Pyun
Xiaoning C. Sheng
Qiaoyin Wu
Catalin Sebastian Zonte
Original Assignee
Gilead Sciences, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences, Inc. filed Critical Gilead Sciences, Inc.
Publication of WO2011156610A2 publication Critical patent/WO2011156610A2/en
Publication of WO2011156610A3 publication Critical patent/WO2011156610A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present application includes novel inhibitors of HCV, compositions containing such compounds, therapeutic methods that include the administration of such compounds Formula (I).
PCT/US2011/039813 2010-06-09 2011-06-09 Inhibitors of hepatitis c virus WO2011156610A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35311310P 2010-06-09 2010-06-09
US61/353,113 2010-06-09

Publications (2)

Publication Number Publication Date
WO2011156610A2 WO2011156610A2 (en) 2011-12-15
WO2011156610A3 true WO2011156610A3 (en) 2012-01-26

Family

ID=44310058

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/039813 WO2011156610A2 (en) 2010-06-09 2011-06-09 Inhibitors of hepatitis c virus

Country Status (4)

Country Link
US (1) US20120053148A1 (en)
AR (1) AR081653A1 (en)
TW (1) TW201210597A (en)
WO (1) WO2011156610A2 (en)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
WO2013090929A1 (en) * 2011-12-15 2013-06-20 Gilead Sciences, Inc. Amino quinoline derivatives inhibitors of hcv
ES2984771T3 (en) 2012-06-13 2024-10-31 Incyte Holdings Corp Substituted tricyclic compounds as FGFR inhibitors
WO2014026125A1 (en) 2012-08-10 2014-02-13 Incyte Corporation Pyrazine derivatives as fgfr inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
DK2986610T5 (en) 2013-04-19 2018-12-10 Incyte Holdings Corp BICYCLIC HETEROCYCLES AS FGFR INHIBITORS
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
TWI699355B (en) 2014-12-24 2020-07-21 美商基利科學股份有限公司 Quinazoline compounds
BR112017013491A2 (en) 2014-12-24 2018-01-09 Gilead Sciences, Inc. fused pyrimidine compounds for the treatment of hiv
NZ733125A (en) 2014-12-24 2018-06-29 Gilead Sciences Inc Isoquinoline compounds for the treatment of hiv
CN118286245A (en) 2014-12-26 2024-07-05 埃莫里大学 N4-hydroxycytidine and derivatives and antiviral uses related thereto
PE20171514A1 (en) 2015-02-20 2017-10-20 Incyte Corp BICYCLE HETEROCYCLES AS FGFR INHIBITORS
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MA41551A (en) 2015-02-20 2017-12-26 Incyte Corp BICYCLIC HETEROCYCLES USED AS FGFR4 INHIBITORS
WO2017019828A1 (en) * 2015-07-30 2017-02-02 Bristol-Myers Squibb Company Aryl substituted bicyclic heteroaryl compounds
AR111960A1 (en) 2017-05-26 2019-09-04 Incyte Corp CRYSTALLINE FORMS OF A FGFR INHIBITOR AND PROCESSES FOR ITS PREPARATION
AU2018378832B9 (en) 2017-12-07 2021-05-27 Emory University N4-hydroxycytidine and derivatives and anti-viral uses related thereto
BR112020022392A2 (en) 2018-05-04 2021-02-02 Incyte Corporation solid forms of a fgfr inhibitor and processes for preparing them
CR20200591A (en) 2018-05-04 2021-03-31 Incyte Corp Salts of an fgfr inhibitor
GB201810581D0 (en) 2018-06-28 2018-08-15 Ctxt Pty Ltd Compounds
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
JP7546596B2 (en) * 2019-04-26 2024-09-06 セルジーン コーポレーション Heterocyclic compounds and their use in helminth infections and diseases - Patents.com
RS64931B1 (en) 2019-06-18 2023-12-29 Pfizer BENZIZOXAZOLE SULFONAMIDE DERIVATIVES
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US12122767B2 (en) 2019-10-01 2024-10-22 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
CN115835908A (en) 2019-10-14 2023-03-21 因赛特公司 Bicyclic heterocycles as FGFR inhibitors
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
CA3163875A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
JP2023505257A (en) 2019-12-04 2023-02-08 インサイト・コーポレイション Derivatives of FGFR inhibitors
WO2021146424A1 (en) 2020-01-15 2021-07-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
KR102463217B1 (en) * 2020-07-13 2022-11-07 한국과학기술연구원 4-aminoquinazoline-2-carboxamide derivatives as protein kinase inhibitors and compositions for preventing, improving or treating cancer containing the same
EP4323405A1 (en) 2021-04-12 2024-02-21 Incyte Corporation Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
EP4352059A1 (en) 2021-06-09 2024-04-17 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004076386A2 (en) * 2003-02-25 2004-09-10 Topotarget Uk Limited Carbamic acid compounds comprising a bicyclic heteroaryl group as hdac inhibitors
WO2004081009A1 (en) * 2003-03-12 2004-09-23 Millennium Pharmaceuticals, Inc. Quinazoline derivatives as tgf-beta inhibitors
WO2005042513A1 (en) * 2003-10-23 2005-05-12 Sterix Limited Phenyl carboxamide and sulfonamide derivatives for use as 11-beta-hydroxysteroid dehydrogenase
WO2005070430A1 (en) * 2004-01-23 2005-08-04 Janssen Pharmaceutica N.V. Quinoline derivatives and use thereof as mycobacterial inhibitors
WO2008014822A1 (en) * 2006-08-03 2008-02-07 Rottapharm S.P.A. 6-1h-imidazo-quinazoline and quinolines derivatives, new potent analgesics and anti-inflammatory agents
WO2008020203A1 (en) * 2006-08-17 2008-02-21 Astrazeneca Ab Pyridinylquinaz0linamine derivatives and their use as b-raf inhibitors
EP2077263A1 (en) * 2008-01-02 2009-07-08 Vereniging voor christelijk hoger onderwijs, wetenschappelijk onderzoek en patiëntenzorg Quinazolines and related heterocyclic compounds and their therapeutic use
WO2009152868A1 (en) * 2008-06-20 2009-12-23 Rottapharm S.P.A. 6-1h-imidazo-quinazoline and quinolines derivatives, new mao inhibitors and imidazoline receptor ligands

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004076386A2 (en) * 2003-02-25 2004-09-10 Topotarget Uk Limited Carbamic acid compounds comprising a bicyclic heteroaryl group as hdac inhibitors
WO2004081009A1 (en) * 2003-03-12 2004-09-23 Millennium Pharmaceuticals, Inc. Quinazoline derivatives as tgf-beta inhibitors
WO2005042513A1 (en) * 2003-10-23 2005-05-12 Sterix Limited Phenyl carboxamide and sulfonamide derivatives for use as 11-beta-hydroxysteroid dehydrogenase
WO2005070430A1 (en) * 2004-01-23 2005-08-04 Janssen Pharmaceutica N.V. Quinoline derivatives and use thereof as mycobacterial inhibitors
WO2008014822A1 (en) * 2006-08-03 2008-02-07 Rottapharm S.P.A. 6-1h-imidazo-quinazoline and quinolines derivatives, new potent analgesics and anti-inflammatory agents
WO2008020203A1 (en) * 2006-08-17 2008-02-21 Astrazeneca Ab Pyridinylquinaz0linamine derivatives and their use as b-raf inhibitors
EP2077263A1 (en) * 2008-01-02 2009-07-08 Vereniging voor christelijk hoger onderwijs, wetenschappelijk onderzoek en patiëntenzorg Quinazolines and related heterocyclic compounds and their therapeutic use
WO2009152868A1 (en) * 2008-06-20 2009-12-23 Rottapharm S.P.A. 6-1h-imidazo-quinazoline and quinolines derivatives, new mao inhibitors and imidazoline receptor ligands

Non-Patent Citations (18)

* Cited by examiner, † Cited by third party
Title
ASTUDILLO SAAVEDRA ET AL.: "Synthesis of new diversely linked biquinoline derivatives by milticomponent imino-Diels-Alder cycloaddition and intramolecular Friedel-Crafts cyclization", SYNTHESIS, vol. 4, 16 December 2009 (2009-12-16), pages 593 - 600, XP002663855 *
BERRY D J ET AL: "Polyhalogenoaromatic Compounds. Part XVII", JOURNAL OF THE CHEMICAL SOCIETY, SECTION C: ORGANIC CHEMISTRY, CHEMICAL SOCIETY. LETCHWORTH, GB, vol. 4, 1 January 1971 (1971-01-01), pages 642 - 645, XP009150925, ISSN: 0022-4952 *
DEMIDOVA AND A V AKSENOV N V: "Investigations In the Field of 2,3'-Biquinolyl. 13. Regioselectivity in the Nitration of 2,3'-Biquinolyls and Their 1',4'-Dihydro Derivatives", CHEMISTRY OF HETEROCYCLIC COMPOUNDS/(A TRANSLATION OF KHIMIYA GETEROTSIKLICHESKIKH SOEDINENII), SPRINGER NEW YORK LLC, US, vol. 38, no. 8, 1 August 2002 (2002-08-01), pages 908 - 912, XP002657683, ISSN: 0009-3122, DOI: 10.1023/A:1020909227484 *
HENRI WAHL ET AL: "SELS QUATERNAIRES DERIVES DES METHYL-2 QUINOXALINES. PREPARATION ET REACTIONS AVEC LES AGENTS MINERAUX BASIQUES", BULLETIN DE LA SOCIETE CHIMIQUE DE FRANCE. 1 PARTIE -CHIMIE ANALYTIQUE, MINERALE ET PHYSIQUE, SOCIETE FRANCAISE DE CHIMIE. PARIS, FR, 1 January 1973 (1973-01-01), pages 1285 - 1287, XP009079628 *
KANG I J ET AL: "Design and synthesis of indole, 2,3-dihydro-indole, and 3,4-dihydro-2H-quinoline-1-carbothioic acid amide derivatives as novel HCV inhibitors", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, ELSEVIER SCIENCE, GB, vol. 19, no. 15, 1 August 2009 (2009-08-01), pages 4134 - 4138, XP026301652, ISSN: 0960-894X, [retrieved on 20090606], DOI: DOI:10.1016/J.BMCL.2009.06.009 *
L.Y. CHIANG: "Chemistry of catalytic dehydrogenative oligomerization of tetrahydroquinoline and structural characterization of nonsubstituted quinoline oligomers", J. AM. CHEM. SOC., vol. 113, 1991, pages 6574 - 6584, XP002663853 *
MANGALAGIU I ET AL: "Trialkylalanes in Palladium-Catalyzed Chemo- and Regioselective Alkylations", TETRAHEDRON LETTERS, ELSEVIER, AMSTERDAM, NL, vol. 37, no. 8, 19 February 1996 (1996-02-19), pages 1309 - 1312, XP004030134, ISSN: 0040-4039, DOI: 10.1016/0040-4039(95)02381-X *
MCNAB H: "13C Nuclear Magnetic Resonance Spectra of Quinoxaline Derivatives", JOURNAL OF THE CHEMICAL SOCIETY, PERKIN TRANSACTIONS 1, CHEMICAL SOCIETY, LETCHWORTH; GB, 1 January 1982 (1982-01-01), pages 357 - 363, XP009154214, ISSN: 0300-922X *
MCNUTT W. S.: "The incorporation of the four nitrogen atoms of purines into the pyrimidine and pyrazine rings of riboflavin", J. AM. CHEM. SOC., vol. 83, no. 10, 1961, pages 2303 - 2307, XP002663858 *
MOVASSAGHI ET AL.: "Synthesis of substituted pyridine derivatives via the ruthenium-catalyzed cycloisomerization of 3-azadienynes", J. AM. CHEM. SOC., vol. 128, 2006, pages 4592 - 4593, XP002663851 *
NILSSON M ET AL: "Synthesis and SAR of potent inhibitors of the Hepatitis C virus NS3/4A protease: Exploration of P2 quinazoline substituents", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, ELSEVIER SCIENCE, GB, vol. 20, no. 14, 15 July 2010 (2010-07-15), pages 4004 - 4011, XP027103972, ISSN: 0960-894X, [retrieved on 20100521] *
PARIS ET AL.: "Anthelmintic quaternary salts. V. 2-(p-dialkylaminophenyl)-1-methylquinolinium salts", J. MED. CHEM., vol. 13, 1970, pages 122 - 124, XP002663856 *
SESTILI I ET AL: "A new synthetic approach of N-(4-amino-2-methylquinolin-6-yl)-2-(4-et hylphenoxymethyl)benzamide (JTC-801) and its analogues and their pharmacological evaluation as nociceptin receptor (NOP) antagonists", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, EDITIONS SCIENTIFIQUE ELSEVIER, PARIS, FR, vol. 39, no. 12, 1 December 2004 (2004-12-01), pages 1047 - 1057, XP004663680, ISSN: 0223-5234, DOI: 10.1016/J.EJMECH.2004.09.009 *
SINGH S P ET AL: "REACTION OF 4-HYDRAZINOQUINOLINES WITH BETA-DIKETONES. SYNTHESIS AND SPECTROSCOPY (1H, 13C NMR, MS) OF SOME PYRAZOLYLQUINOLINES", JOURNAL OF HETEROCYCLIC CHEMISTRY, WILEY-BLACKWELL PUBLISHING, INC, US, vol. 26, 1 May 1989 (1989-05-01), pages 733 - 738, XP000985609, ISSN: 0022-152X, DOI: 10.1002/JHET.5570260340 *
SUEKI ET AL.: "One-pot synthesis and fluorescence properties of 2-arylquinolines", BULL. CHEM. SOC. JPN, vol. 83, no. 4, 26 March 2010 (2010-03-26), pages 385 - 390, XP002663854 *
THORNTON ET AL.: "Quinazoline antifolates inhibiting thymidylate synthase: 4-thio-substituted analogues", J. MED. CHEM., vol. 34, 1991, pages 978 - 984, XP002663857 *
WOLF F J ET AL: "Substituted Sulfaquinoxalines. III. Extension of the Glyoxalate Synthesis of 2-Aminoquinoxaline", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, AMERICAN CHEMICAL SOCIETY, WASHINGTON, DC; US, vol. 71, 1 January 1949 (1949-01-01), pages 6 - 10, XP003003397, ISSN: 0002-7863, DOI: 10.1021/JA01169A001 *
YI-ZHEN HU: "Friedländer approach for the incorporation of 6-bromoquinoline into novel chelating ligands", ORGANIC LETTERS, vol. 5, no. 13, 2003, pages 2251 - 2253, XP002663852 *

Also Published As

Publication number Publication date
WO2011156610A2 (en) 2011-12-15
TW201210597A (en) 2012-03-16
US20120053148A1 (en) 2012-03-01
AR081653A1 (en) 2012-10-10

Similar Documents

Publication Publication Date Title
WO2011156610A3 (en) Quinoline and isoquinoline derivatives as inhibitors of hepatitis c virus
PH12020550552A1 (en) Inhibitors of hepatitis c virus
MX2012008221A (en) Inhibitors of flaviviridae viruses.
MX2012008211A (en) Inhibitors of flaviviridae viruses.
WO2011153157A3 (en) Benzoquinolone inhibitors of vmat2
PH12013501543A1 (en) Hepatitis c virus inhibitors
MX2013006475A (en) Macrocyclic inhibitors of flaviviridae viruses.
MX337936B (en) Hepatitis c virus inhibitors.
MX2013001579A (en) Hepatitis c virus inhibitors
NZ703066A (en) Macrocyclic inhibitors of flaviviridae viruses
MX2012000959A (en) Inhibitors of flaviviridae viruses.
NZ724503A (en) Macrocyclic inhibitors of flaviviridae viruses
PH12014502739A1 (en) Macrocyclic inhibitors of flaviviridae viruses
MX2010008699A (en) Heterocyclic derivatives as hepatitis c virus inhibitors.
WO2012040389A3 (en) Substituted bicyclic hcv inhibitors
PH12013502190A1 (en) Hepatitis c virus inhibitors
IN2012DN01855A (en)
WO2010021717A3 (en) Hcv protease inhibitors
PH12013502177A1 (en) Hepatitis c virus inhibitors
WO2011150190A3 (en) Hcv inhibitor compounds and methods of use thereof
MX2013014002A (en) Hepatitis c virus inhibitors.
PH12015500814A1 (en) Hepatitis c virus inhibitors
MX2015013224A (en) Macrocyclic and bicyclic inhibitors of hepatitis c virus.
TN2013000335A1 (en) Hepatitis c virus inhibitors
MY163245A (en) Hepatitis c virus inhibitors

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11726615

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11726615

Country of ref document: EP

Kind code of ref document: A2